Introduction —
This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.
The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.
Links to related guidelines are provided separately:
●(See "Society guideline links: Lipid disorders in adults".)
●(See "Society guideline links: Hypertension in children".)
●(See "Society guideline links: Obesity in children".)
●(See "Society guideline links: Acute kidney injury in children".)
●(See "Society guideline links: Chronic kidney disease in children".)
●(See "Society guideline links: Nephrotic syndrome in children".)
●(See "Society guideline links: Kawasaki disease".)
●(See "Society guideline links: Diabetes mellitus in children".)
●(See "Society guideline links: Smoking cessation, e-cigarettes, and tobacco control".)
●(See "Society guideline links: Healthy diet in children and adolescents".)
Canada
●Canadian Cardiovascular Society (CCS)/Canadian Pediatric Cardiology Association (CPCA): Clinical practice update on The detection, evaluation, and management of dyslipidemia in children and adolescents (2022)
●Canadian Society of Clinical Chemists (CSCC): Harmonized clinical laboratory lipid reporting recommendations on the basis of the 2021 Canadian Cardiovascular Society lipid guidelines (2022)
●Canadian Cardiovascular Society (CCS): Position statement on familial hypercholesterolemia, update (2018)
United States
●American Heart Association (AHA): A scientific statement on cardiovascular management of patients undergoing hematopoietic stem cell transplantation (2024)
●US Preventive Services Task Force (USPSTF): Final recommendation statement on lipid disorders in children and adolescents – Screening (2023)
●AHA: Scientific statement on cardiovascular risk reduction in high-risk pediatric patients (2019)
●AHA/American College of Cardiology (ACC)/American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR)/American Academy of Physician Assistants (AAPA)/Association of Black Cardiologists (ABC)/American College of Preventive Medicine (ACPM)/American Diabetes Association (ADA)/American Geriatrics Society (AGS)/American Pharmacists Association (APhA)/American Society for Preventive Cardiology (ASPC)/National Lipid Association (NLA)/Preventive Cardiovascular Nurses Association (PCNA): Guideline on the management of blood cholesterol (2018)
●American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE): Guidelines for management of dyslipidemia and prevention of cardiovascular disease (2017)
●AHA: Scientific statement on cardiovascular consequences of childhood secondhand tobacco smoke exposure – Prevailing evidence, burden, and racial and socioeconomic disparities (2016)
●AHA: Scientific statement on major depressive disorder and bipolar disorder predispose youth to accelerated atherosclerosis and early cardiovascular disease (2015)
●AHA: Scientific statement on the agenda for familial hypercholesterolemia (2015)
●National Heart, Lung, and Blood Institute (NHLBI): Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents (2012)
●NLA: Clinical guidance on familial hypercholesterolemia – Screening, diagnosis and management of pediatric and adult patients (2011)
●American Academy of Pediatrics (AAP): Clinical report for lipid screening and cardiovascular health in childhood (2008)
Europe
●European Atherosclerosis Society (EAS): Consensus statement on homozygous familial hypercholesterolaemia – New treatments and clinical guidance (2023)
●European Society of Cardiology (ESC): Guidelines on cardiovascular disease prevention in clinical practice (2021)
●EAS and European Federation of Clinical Chemistry and Laboratory Medicine (EFLM): Consensus-based recommendations from quantifying atherogenic lipoproteins for lipid-lowering strategies (2020)
●EAS: Consensus statement on rare dyslipidaemias, from phenotype to genotype to management (2019)
●ESC/EAS: Guidelines for the management of dyslipidaemias – Lipid modification to reduce cardiovascular risk (2019)
●EAS and EFLM: Consensus statement on quantifying atherogenic lipoproteins – Current and future challenges in the era of personalized medicine and very low concentrations of LDL cholesterol (2018)
●ESC/EAS: Consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors – Practical guidance for use in patients at very high cardiovascular risk (2017)
●ESC/EAS: Practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia, update (2017)
●EAS: Familial hypercholesterolaemia in children and adolescents – Gaining decades of life by optimizing detection and treatment (2015)
●EAS: Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease (2014)
●EAS: Position paper on homozygous familial hypercholesterolaemia – New insights and guidance for clinicians to improve detection and clinical management (2014)
●EAS: Consensus statement on familial hypercholesterolaemia is underdiagnosed and undertreated in the general population – Guidance for clinicians to prevent coronary heart disease (2013)
United Kingdom
●Hyperlipidaemia Education and Atherosclerosis Research Trust United Kingdom (HEART UK): Statement of care for current management of children and young people with heterozygous familial hypercholesterolaemia (2019)
●National Institute for Health and Care Excellence (NICE): Clinical guideline on familial hypercholesterolaemia – Identification and management (2008, updated 2019)
●NICE: Quality standard on familial hypercholesterolaemia (2013, updated 2017)
●HEART UK: Statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom (2016)
AUSTRALIA–NEW ZEALAND
●Cardiac Society of Australia and New Zealand (CSANZ): Diagnosis and management of familial hypercholesterolaemia – Position statement (2016)
Japan
●[In English] Japan Pediatric Society (JPS) and Japan Atherosclerosis Society (JAS): Guidelines for the diagnosis and treatment of pediatric familial hypercholesterolemia (2022)
●[In Japanese] JPS and JAS: Guidelines for the diagnosis and treatment of pediatric familial hypercholesterolemia (2022)
●[In Japanese] JAS: Guidelines for prevention of atherosclerotic cardiovascular diseases (2022)
●[In English] JAS: Guidelines for prevention of atherosclerotic cardiovascular diseases (2022)
●[In English] JAS: Guidelines on the clinical evaluation of medicinal products for treatment of dyslipidemia (2020)
●[In English] Japanese Circulation Society (JCS): 2013 guidelines for the diagnosis and management of cardiovascular sequelae in Kawasaki disease (published 2014)
